Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma

Journal of Cardiac Failure

Volumn 21, Issue 2, 2015, Pages 138-144

  Grandin, E Wilson ^a   Ky, Bonnie ^a   Cornell, R Frank ^b   Carver, Joseph ^a   Lenihan, Daniel J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carfilzomib; chemotherapy; heart failure; proteasome inhibitor

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CARFILZOMIB; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FUROSEMIDE; IMMUNOGLOBULIN KAPPA CHAIN; LENALIDOMIDE; LISINOPRIL; LOSARTAN; MELPHALAN; PREDNISONE; THALIDOMIDE; TROPONIN I; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOPULMONARY EXERCISE TEST; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DIASTOLIC DYSFUNCTION; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTENSION; INDUCTION CHEMOTHERAPY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LOW DRUG DOSE; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL EDEMA; PRIORITY JOURNAL; QT PROLONGATION; ST SEGMENT ELEVATION; T WAVE INVERSION; TISSUE DOPPLER IMAGING; TREATMENT DURATION; TREATMENT WITHDRAWAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY; CASE REPORT; COMPLICATION; ECHOGRAPHY; TREATMENT OUTCOME;

AGED; CARDIOTOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; TREATMENT OUTCOME;

EID: 84921859531     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.11.008     Document Type: Article

References (32)

1. S. Kumar, I. Flinn, P.G. Richardson, P. Hari, N. Callander, and S.J. Noga Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood 119 2012 4375 4382
2. S.V. Rajkumar Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am Soc Hematol Educ Program 2012 2012 354 361
3. R. Vij, M. Wang, J.L. Kaufman, S. Lonial, A.J. Jakubowiak, and A.K. Stewart An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Blood 119 2012 5661 5670
4. S. Jagannath, R. Vij, A.K. Stewart, S. Trudel, A.J. Jakubowiak, and T. Reiman An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma Clin Lymphoma Myeloma Leuk 12 2012 310 318
5. D.S. Siegel, T. Martin, M. Wang, R. Vij, A.J. Jakubowiak, and S. Lonial A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
6. M. Patel, and M. Majetschak Distribution and interrelationship of ubiquitin proteasome pathway component activities and ubiquitin pools in various porcine tissues Physiol Res 56 2007 341 350
7. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, and M.N. Ho Antitumor activity of PR-171, a novel irreversible inhibitor of the proteosome Cancer Res 67 2007 6383 6391
8. M.S. Willis, and C. Patterson Proteotoxicity and cardiac dysfunction - Alzheimer's disease of the heart N Engl J Med 368 2013 455 464
9. P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, and T. Facon Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
10. J.P. Laubauch, J.F. San Miguel, P. Sonneveld, R.Z. Orlowski, P. Moreau, and L. Rosinol Quantifying the risk of heart failure associated with proteasome inhibition: a retrospective analysis of heart failure reported in phase 2 and phase 3 studies of bortezomib (BTZ) in multiple myeloma (MM) (abstract) Blood 122 2013 3187
11. J. Herrmann, C. Wohlert, A.M. Saguner, A. Flores, L.L. Nesbitt, and A. Chade Primary proteasome inhibition results in cardiac dysfunction Eur J Heart Fail 15 2013 614 623
12. D. Nowis, M. Maczewski, U. Mackiewicz, M. Kujawa, A. Ratajska, and M.R. Wieckowski Cardiotoxicity of the anticancer therapeutic agent bortezomib Am J Pathol 176 2010 2658 2668
13. E. Orciuolo, G. Buda, N. Cecconi, S. Galimberti, D. Versari, and G. Cervetti Unexpected cardiotoxicity in haematological bortezomib treated patients Br J Haematol 138 2007 396 403
14. J. Voortman, and G. Giaccone Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report BMC Cancer 6 2006 129
15. A. Hacihanefioglu, P. Tarkun, and E. Gonullu Acute severe cardiac failure in a myeloma patient due to proteosome inhibitor bortezomib Int J Hematol 88 2008 219 222
16. A. Palumbo, F. Gay, A. Falcone, N. Pescosta, V. Callea, and T. Caravita Bortezomib, doxorubicin, and dexamethasone in advanced multiple myeloma Ann Oncol 19 2008 1160 1165
17. D. Siegel, T. Martin, A. Nooka, D. Harvey, R. Vij, and R. Niesvizky Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies Haematologica 2013 98
18. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
19. N. Lendvai, P. Hilden, S. Devlin, H. Landau, H. Hassoun, and A.M. Lesokhin A phase 2 single-center study of carfilzomib 56mg/m2 with or without low-dose dexamethasone in relapsed or refractory multiple myeloma Blood 124 2014 899 906
20. K.P. Papadopoulos, H.A. Burris, M. Gordon, P. Lee, E.A. Sausville, and P.J. Rosen A phase I/II study of carfilzomib 2-10 min infusion in patients with advanced solid tumors Cancer Chemother Pharmacol 72 2013 861 868
21. P. Tannous, H. Zhu, A. Nemchenko, J.M. Berry, J.L. Johnstone, and J.M. Shelton Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy Circulation 117 2008 3070 3078
22. A. Sanbe, H. Osinka, J.E. Saffitz, C.G. Glabe, R. Kayed, and A. Maloyan Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis Proc Natl Acad Sci 101 2004 10132 10136
23. M. Tang, J. Li, W. Huang, H. Su, Q. Liang, and Z. Tian Proteasome functional insufficiency activates the calcineufin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts Cardiovasc Res 88 2010 424 433
24. P. Wang, J. Calise, K. Powell, A. Divald, and S.R. POwell Upregulation of proteasome activity rescues cardiomyocytes following pulse treatment with a proteasome inhibitor Am J Cardiovasc Dis 4 2014 6 13
25. A. Nencioni, F. Grunebach, F. Patrone, A. Ballestero, and P. Brossart Proteasome inhibitors: antitumor effects and beyond Leukemia 21 2007 30 36
26. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, and M. Velankar A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib Cancer Cell 8 2005 407 419
27. P.G. Richardson, W. Xie, C. Mitsiades, A. Chanan-Khan, S. Lonial, and H. Hassoun Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy J Clin Oncol 27 2009 3518 3525
28. I.M. Ghobrial, P.G. Richardson, and K.C. Anderson Bortezomib in the treatment of multiple myeloma M.J. Parnham, J. Bruinvels, 2010 Springer Berlin 19 95
29. O.A. O'Connor, A.K. Stewart, M.K. Vallone, C.J. Molineaux, L.A. Kunkel, and J.F. Gerecitano A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 2009 7085 7091
30. P.S. Hall, L.C. Harshman, S. Srinivas, and R. Witteles The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients JACC Heart Fail 1 2013 72 78
31. D. Skovgaard, P. Hasbak, and A. Kjaer BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography PLoS One 9 2014 e96736
32. R.Z. Orlowski, A. Nagler, P. Sonneveld, J. Blade, R. Hajek, and A. Spencer Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 2007 3892 3901